Skin Prick Testing to Identify Food Allergens in 8393 Children and Adolescents with Asthma in Chongqing, Southwest China.
CONCLUSIONS Identifying allergens is important for the diagnosis and management of allergic disorders, and for performing immunotherapy. PMID: 31676746 [PubMed - in process]
AbstractPurpose of ReviewInvestigational allergen immunotherapies (AITs) including oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) have proven to increase allergen thresholds required to elicit an allergic reaction in a majority of subjects. However, these studies lack consistent biomarkers to predict therapy outcomes. Here, we will review biomarkers that are currently being investigated for AIT.Recent FindingsThe mechanisms underlying the therapeutic benefit of AIT involve various cell types, including mast cells, basophils, T cells, and B cells. Skin prick and basophil act...
Peanut allergy affects 1-2% of individuals in the United States, and is increasing in prevalence.1-4 Although there is accumulating data on immunotherapy for peanut allergy,5-8 the cornerstone of management remains strict avoidance of peanut protein, maintenance of an emergency action plan and prompt use of epinephrine to treat systemic reactions in case of an accidental exposure, which occurs in up to 12-15% of peanut-allergic individuals annually.9,10 Peanut allergy significantly impacts quality of life,11 as it is typically lifelong, is the leading cause of food-induced anaphylaxis in children, and the leading cause of ...
AbstractPurpose of ReviewOver the last decade, there has been a spark in innovation in the development of therapies for food allergy. Herein, we describe the background and recent advances for food-specific immunotherapies including epicutaneous (EPIT), sublingual (SLIT), and subcutaneous (SCIT).Recent FindingsStudies have progressed most quickly for the treatment of peanut allergy. Data from the phase 3 EPIT trial add to the accumulating evidence that this will be a viable therapy for peanut allergy. Studies for SLIT and SCIT remain in earlier phases with promising results.SummaryThis is an exciting era for the treatment ...
For children with peanut allergy (PA) and their families, living with the possibility of a potentially life-threatening reaction can decrease health-related quality of life (HRQL). Reducing the risk of reactions due to accidental ingestion through immunotherapy may improve HRQL. In a Phase IIb trial, daily epicutaneous immunotherapy (EPIT) with 250- μg peanut patch (∼1/1000 of 1 peanut kernel) resulted in significant treatment response versus placebo. Objectives of this qualitative, multisite, retrospective study were to assess patients’ HRQL, treatment expectations, and satisfaction.
Pollen food allergy syndrome (PFAS) is widely prevalent, affecting 5 percent of the population(1). Subcutaneous allergen immunotherapy (SCIT) has been shown to be effective in reducing PFAS symptoms in adults(2). However, this effect has not been widely demonstrated in a pediatric population, which this study will examine.
This study describes a single center’s experience with milk OIT, which may be informative to practicing allergists.
The prevalence of food allergies (FA) is increasing. Oral immunotherapy (OIT) is an emerging FA therapy, but the practice requirements necessary for its implementation are unclear. We investigated patterns of effective clinical practice logistics for implementing OIT compared to subcutaneous immunotherapy (SCIT) among allergists/immunologists who prescribe both treatments.
The rising incidence of pediatric food allergy results in significant health care burden and family stress. Oral immunotherapy (OIT) has been shown to induce tolerance to peanut, milk and egg. OIT for other foods, particularly multiple foods simultaneously, has not been thoroughly studied.
CONCLUSION: A similar approach to that used for peanut OIT can be taken for non-peanut foods, and for multiple foods simultaneously. High baseline allergy test results are not a contraindication to OIT. PMID: 31494236 [PubMed - as supplied by publisher]
Peanut allergy is a generally persistent, sometimes life-threatening food allergy that is increasing in prevalence in Western countries.1 There are no FDA-approved therapies for treatment of peanut allergy, and patients must strictly avoid peanut and be prepared to use rescue medication upon symptoms due to unintentional peanut ingestion.1 However, complete avoidance of peanut is difficult at least in part due to its widespread use as a food ingredient in packaged foods and in restaurant or catered meals.